1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Hikma Outlines Injectables Growth Amid Slow Start For Generics

Generics Revenues Expected To Be Weighted Towards Second Half Of 2022

 
• By Dave Wallace

Hikma has set out fresh growth forecasts for its injectables business after completing its acquisition of Custopharm. Meanwhile, a slow start to the year for the firm’s generics business amid a “challenging pricing environment” is expected to be followed by higher revenues towards the end of the year.

Growth man drawing graph pen
Hikma has set out its injectables growth expectations after acquiring Custopharm • Source: Christian Horz / Alamy Stock Photo

Hikma says it now expects to achieve global injectables sales growth “in the mid to high-single digits” in 2022, up from previous guidance of low to mid-single digits, after completing its acquisition of Custopharm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.